Fact CheckerSign in

NCT06911931Recruiting

Visual Perception in Schizophrenia

Visual Perception in Schizophrenia: Assessing Predictive Processing in the Earliest Stages of the Visual Cortical Hierarchy

Source: ClinicalTrials.gov · Last updated 12 Nov 2025

Brief summary (registry, in English)

This study aims to identify novel markers of psychosis using electroencephalography (EEG).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
84 (estimated)
First submitted
28 Mar 2025
Start date
3 Nov 2025
Primary completion date
31 Jan 2027
Lead sponsor
University of Rochester
NCT number
NCT06911931

What you commit to

  • Study type: Interventional
  • Planned participants: 84
  • From 3 Nov 2025 to the primary completion date, 31 Jan 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:
    • Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
    • Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
    • Actively intoxicated, as shown via patient self-report or staff report;
    • Substance use disorder in the past 3 months;
    • Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
    • Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
    • Being in a current manic state
    • Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
    • Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
    • Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
    • Lazy eye or squint or other known ocular pathology
  • Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
  • Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days

Other illness

  • Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
  • Any lifetime psychotic disorder (as assessed by SCID/or SSD);
  • History of psychiatric hospitalization;
  • First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.

Other

  • All subjects
  • Healthy Control Subjects
  • Case-match Control Non-ill Subjects
  • Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
  • Persistent threshold psychotic symptoms
  • Bipolar Subjects
  • Persistent threshold psychotic symptoms

Who the study is looking for

  • All Subjects
  • Aged 18-65
  • 20/32 visual acuity or better (using in-house optical correction, if necessary)
  • An ability to speak English well enough to complete study assessments and to consent to the study
  • Subjects with Schizophrenia-Spectrum Disorder
  • Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
  • Subjects with Bipolar Disorder
  • Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Rochester
Coordinator of this site? Confirm its status
RochesterUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.